<!DOCTYPE html>
<html lang="en">
    <head>
        <title>displaCy</title>
    </head>

    <body style="font-size: 16px; font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol'; padding: 4rem 2rem; direction: ltr">
<figure style="margin-bottom: 6rem">
<div class="entities" style="line-height: 2.5; direction: ltr">==== Front</br> J EpidemiolJ EpidemiolJournal of Epidemiology0917-50401349-9092Elsevier S0917-5040(16)30081-810.1016/j.je.2016.12.006Original ArticleOverview of BioBank Japan follow-up data in 32 diseases Hirata Makoto aNagai Akiko bKamatani Yoichiro cNinomiya Toshiharu dTamakoshi Akiko eYamagata Zentaro fKubo Michiaki gMuto Kaori bKiyohara Yutaka hMushiroda Taisei iMurakami Yoshinori jYuji Koichiro kFurukawa Yoichi lZembutsu Hitoshi mnTanaka Toshihiro opqOhnishi Yozo orNakamura Yusuke msBioBank Japan Cooperative Hospital GroupShiono Masaki vMisumi Kazuo vKaieda Reiji vHarada Hiromasa vMinami Shiro wWatanabe Atsushi wEmoto Naoya wTakahashi Kazuhisa xTakeda Satoru xFunaki Toshinari xAsai Satoshi yMoriyama Mitsuhiko yTakahashi Yasuo yFujioka Tomoaki zObara Wataru zMori Seijiro aaIto Hideki aaNagayama Satoshi abMiki Yoshio abMasumoto Akihide acYamada Akira acNishizawa Yasuko adKodama Ken adKutsumi Hiromu aeSugimoto Yoshihisa aeKoretsune Yukihiro afKusuoka Hideo afYoshimori Kozo agv Tokushukai Hospitals, Japanw Nippon Medical School, Japanx Juntendo University, Japany Nihon University, Japanz Iwate Medical University, Japanaa Tokyo Metropolitan Institute of Gerontology, Japanab The Cancer Institute Hospital of JFCR, Japanac Aso Iizuka Hospital, Japanad Osaka Medical Center for Cancer and Cardiovascular Diseases, Japanae Shiga University of Medical Science, Japanaf National Hospital Organization, Osaka National Hospital, Japanag Fukujuji Hospital, Japan uMatsuda Koichi kmatsuda@k.u-tokyo.ac.jpmt∗a Laboratory of Genome Technology, Institute of Medical Science, The University of Tokyo, Tokyo, Japanb Department of Public Policy, Institute of Medical Science, The University of Tokyo, Tokyo, Japanc Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japand Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japane Department of Public Health, Hokkaido University Graduate School of Medicine, Sapporo, Japanf Department of Health Sciences, University of Yamanashi, Yamanashi, Japang RIKEN Center for Integrative Medical Sciences, Yokohama, Japanh Hisayama Research Institute for Lifestyle Diseases, Fukuoka, Japani Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japanj Division of Molecular Pathology, Institute of Medical Science, The University of Tokyo, Tokyo, Japank Project Division of International Advanced Medical Research, Institute of Medical Science, The University of Tokyo, Tokyo, Japanl Division of Clinical Genome Research, Institute of Medical Science, The University of Tokyo, Tokyo, Japanm Laboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japann Division of Genetics, National Cancer Center Research Institute, Tokyo, Japano SNP Research Center, RIKEN Yokohama Institute, Yokohama, Japanp Department of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japanq Bioresource Research Center, Tokyo Medical and Dental University, Tokyo, Japanr Shinko Clinic, Medical Corporation Shinkokai, Tokyo, Japans Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, USAt Laboratory of Clinical Genome Sequencing, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan∗ Corresponding author. Laboratory of Clinical Genome Sequencing, Graduate School of Frontier Sciences, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.Laboratory of Clinical Genome SequencingGraduate School of Frontier SciencesThe University of Tokyo4-6-1 ShirokanedaiMinato-kuTokyo108-8639Japan kmatsuda@k.u-tokyo.ac.jpu Hospital Group members are listed in Appendix A.</br> </br> Conclusions</br> 
<mark class="entity" style="background: #FF00FF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    This
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">FP</span>
</mark>
 is the first report to perform 
<mark class="entity" style="background: #FF00FF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    follow-up survival analysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">FP</span>
</mark>
 across 
<mark class="entity" style="background: #FF00FF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    various
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">FP</span>
</mark>
 common diseases. Further studies should use detailed clinical and genomic information to identify predictors of mortality in patients with common diseases, contributing to the implementation of personalized medicine.</br> </br> Thirty-one of the 32 diseases were categorized into seven groups: 
<mark class="entity" style="background: #FF0000; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malignant neoplasms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">FN</span>
</mark>
, 
<mark class="entity" style="background: #00FF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    liver disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">TP</span>
</mark>
, 
<mark class="entity" style="background: #00FF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cerebrovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">TP</span>
</mark>
, 
<mark class="entity" style="background: #00FF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cardiovascular disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">TP</span>
</mark>
, 
<mark class="entity" style="background: #00FF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">TP</span>
</mark>
, 
<mark class="entity" style="background: #00FF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    metabolic disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">TP</span>
</mark>
, and 
<mark class="entity" style="background: #00FF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    locomotive disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">TP</span>
</mark>
 (Table 1). 
<mark class="entity" style="background: #FF00FF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Further survival analysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">FP</span>
</mark>
 in each disease category also found a 
<mark class="entity" style="background: #FF00FF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    poorer prognosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">FP</span>
</mark>
 among male subjects, across all disease categories (Fig. 2). Even in 
<mark class="entity" style="background: #FF00FF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    relative survival analysis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">FP</span>
</mark>
, some disease categories, such as 
<mark class="entity" style="background: #FF0000; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    malignant neoplasms
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">FN</span>
</mark>
, 
<mark class="entity" style="background: #00FF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    liver disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">TP</span>
</mark>
, 
<mark class="entity" style="background: #00FF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    respiratory disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">TP</span>
</mark>
, and 
<mark class="entity" style="background: #00FF00; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    locomotive disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">TP</span>
</mark>
, exhibited a 
<mark class="entity" style="background: #FF00FF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    poorer prognosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">FP</span>
</mark>
 among male subjects.</br></div>
</figure>
</body>
</html>